Brace yourself: Drug prices are set to soar again in 2026, despite promises of relief. A new report reveals that at least 350 medications in the U.S. are expected to see price hikes next year, leaving many wondering if the Trump administration's efforts to curb costs have fallen short. But here's where it gets controversial: this surge comes on the heels of the White House's celebrated Most Favored Nation (MFN) policy, which was touted as a game-changer for affordability.
According to data from healthcare research firm 3 Axis Advisors, first reported by Reuters, the number of drugs facing price increases in 2026 surpasses last year's total of over 250. The median price hike is projected to hover around 4%, a figure that might seem modest but can add up significantly for patients relying on multiple medications. And this is the part most people miss: even companies like Pfizer and GSK, which agreed to the MFN policy, are among those planning to raise prices.
President Trump hailed the MFN agreements as “the greatest victory for patient affordability in the history of American health care,” emphasizing that drugmakers would offer their products at the lowest global price and provide direct-to-consumer options through the upcoming TrumpRx platform. “The pharmaceutical companies were difficult, but they also love our country,” he added. However, these agreements were secured under the threat of tariffs, raising questions about their sustainability and the true willingness of drugmakers to prioritize affordability.
Here’s the catch: The MFN policy primarily impacts the Medicaid program, which already guarantees the lowest prices for its patients. For the majority of Americans on commercial health plans, the benefits may be negligible. Critics, including the Centre for Economic Policy Research, argue that the policy fails to address the root cause of high drug costs: patent monopolies. Without tackling this issue, price negotiations and MFN deals may only scratch the surface of a much deeper problem.
As we approach 2026, the question remains: Will these measures truly make medications more affordable, or are they just a band-aid on a broken system? What do you think? Does the MFN policy go far enough, or is it time for a more radical approach to drug pricing? Let us know in the comments—this is a conversation that needs your voice.
